❌

Reading view

Embodied-BenchForge: A Closed-Loop Agentic Workflow for Embodied Benchmark Construction

arXiv:2609.13082v1 Announce Type: new Abstract: Agentic systems offer a promising way to automate embodied benchmark construction, but existing approaches typically cover isolated stages or remain specialized to predefined environments and task families. More importantly, multi-step construction produces dependent intermediate artifacts that are often passed downstream without artifact-specific verification, allowing local defects to propagate into the final benchmark. We present Embodied-BenchForge, an agentic framework that transforms user-specified evaluation intents into complete embodied benchmark artifacts. It formulates construction as Closed-Loop Benchmark Synthesis, integrating forward artifact synthesis with backward verification and repair. Skill-Orchestrated Artifact Synthesis composes typed and reusable skills into executable workflows, while an artifact dependency graph records intermediate outputs and their dependencies. Requirement-Guided Verification and Repair applies artifact-specific contracts throughout construction and uses provenance to trigger local re-execution or upstream rollback when verification fails. Embodied-BenchForge constructs six benchmarks covering diverse embodied scenarios in the Offline EQA Track, together with one interactive benchmark containing 220 executable tasks in the Interactive Embodied Track. Evaluations of representative MLLMs and embodied agents show that the benchmarks distinguish model capabilities in both observation-based understanding and closed-loop execution. Quality assessment and ablations validate benchmark quality and the effectiveness of verification and repair, while repair and skill-reuse analyses demonstrate efficient localized recovery and cross-benchmark reusability.
  •  

Multi-Omics-Enabled Precision Strategies for Overcoming CAR-T Therapy Limitations in Gastrointestinal Malignancies

Biofactors. 2026 Sep-Oct;52(5):e70150. doi: 10.1002/biof.70150.

ABSTRACT

Gastrointestinal malignancies, including gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma, remain major causes of cancer-related morbidity and mortality worldwide. Although chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, its efficacy in gastrointestinal solid tumors remains limited by antigen heterogeneity, insufficient trafficking and infiltration, immunosuppressive tumor microenvironments, on-target off-tumor toxicity, and adaptive resistance. In this review, we summarize the current landscape of CAR-T therapy in gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer, with a focus on representative target antigens and emerging biomarker strategies. We further discuss two major categories of biomarkers: target antigen-related biomarkers and conventional dynamic biomarkers, including serum tumor markers, cytokine changes, CAR-T expansion kinetics, and antigen-loss monitoring. In addition, we highlight how single-cell ribonucleic acid sequencing and spatial transcriptomics provide complementary insights into cellular states, immune exhaustion, stromal barriers, and spatially restricted immune exclusion. By integrating these multi-omics approaches with biomarker-guided patient stratification and next-generation CAR-T engineering, gastrointestinal solid tumor CAR-T therapy may evolve from empirical optimization toward mechanism-driven and precision-guided clinical translation.

PMID:42717494 | PMC:PMC13558850 | DOI:10.1002/biof.70150

  •  
❌